MedPath

Neuromuscular Electrical Stimulation in Critically Ill Patients.

Not Applicable
Suspended
Conditions
Rehabilitation
Critical Care
Interventions
Device: Neuromuscular Electrical Stimulation
Registration Number
NCT03815994
Lead Sponsor
University of Sao Paulo
Brief Summary

The study will investigate the effects of neuromuscular electrical stimulation (NMES) in critically ill patients. The objective of this study will be investigate the effects of neuromuscular electrical stimulation (NMES) in critically ill patients.

Detailed Description

The study will investigate the effects of neuromuscular electrical stimulation (NMES) in critically ill patients. It will be a randomised crossover clinical trial. Thirty-one patients will enrolled. Patients will be selected, randomly, to the intervention Protocol (decubitus position with the limbs raised and NMES) and control (decubitus position with the limbs raised without NMES).The patients will be allocated in Group 1 (intervention and control) or group 2 (control and intervention) with a wash-out period of 4 to 6 hours between them.

The main outcome will be metabolic data. Linear mixed model will be used for analysis of dependent variables and estimated values of the mean of the differences of each effect.

The results of this study will allow better understanding of the metabolic effects of NMES in patients critically ill.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
31
Inclusion Criteria
  • All patients that will be admitted to the intensive care unit
  • Hemodynamic stability
  • Mechanical ventilation.
Exclusion Criteria
  1. In general:

    • a. Pregnant women
    • b. Brain death
    • c. Neuromuscular diseases
    • d. Use of pre-existing neuromuscular blocker in the last 24 hours, prior to the study protocol.
  2. Contraindications for the use of NMES:

    • a. Fractures
    • b. Burns
    • c. Skin lesions
    • d. Systemic vascular impairment diseases such as systemic lupus erythematosus, thromboembolic disease, deep vein thrombosis (which was not therapeutically anticoagulated for a time greater than 36 hours)
    • e. Lower limb amputations
    • f. Cardiac pacemaker,
    • g. Thrombocytopenia less than 20,000/mm3
    • h. BMI greater than 35 kg/m2
    • i. Important lower extremity oedema
    • j. Agitation and/or signs of pain during the electrical stimulation.
  3. Contraindications to begin or continue NMES procedure:

    • a. Mean arterial blood pressure less than 65 mmHg
    • b. Use of vasopressor >50% of themaximum dose (dopamine >12.5 μg/kg per minute; vasopressin >0.02U/min and norepinephrine >1 μg/kg per minute),
    • c. Heart rate <50 or >140bpm
    • d. Arrhythmias with hemodynamic consequences
    • e. Myocardial ischemia,
    • f. Temperature <34 or >39oC
    • g. Intracranial pressure >20 cmH2O
    • h. Decrease in 10% of SpO2 baseline value or <88% for more than one minute.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
group 2Neuromuscular Electrical StimulationDecubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
Experimental: group 1Neuromuscular Electrical StimulationNeuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
Primary Outcome Measures
NameTimeMethod
Change of Oxygen consumption (VO2),from baseline and interventions.VO2 will be taken during the each intervention, it will be taken only the first day

Change of Oxygen consumption (VO2) will be evaluated by calorimetry

Secondary Outcome Measures
NameTimeMethod
Change of Carbon dioxide production (VCO2) from baseline and interventions.VCO2 will be taken during the each intervention, it will be taken only the first day

Change of Carbon dioxide production (VCO2) will be evaluated by calorimetry

Trial Locations

Locations (1)

Clinics Hospital

🇧🇷

Ribeirão Preto, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath